Samuel C. Blackman
HEAD OF R&D · Day One Biopharmaceuticals, Inc.
- 2024
- Dec 12, 2024
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Samuel C. Blackman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jeremy Bender - $321K in DAWN purchases and sales in the last 12 months
- Adam Dubow - $113K in DAWN purchases and sales in the last 12 months
- Charles N. York II - $107K in DAWN purchases and sales in the last 12 months
- Lauren Merendino - $101K in DAWN purchases and sales in the last 12 months
- Michael Vasconcelles - $32K in DAWN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Samuel C. Blackman?
Samuel C. Blackman is a corporate insider, tracked as HEAD OF R&D of Day One Biopharmaceuticals, Inc. (DAWN). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Samuel C. Blackman last file a Form 4?
The most recent primary Form 4 on record is dated 12 December 2024, one of 5 filings going back to 2024.
Has Samuel C. Blackman been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($1.07M) across all tracked filings.
